Avadel Pharmaceuticals — Flamel Technologies — Investor Presentation (February 2016)
37 slides from Avadel Pharmaceuticals's investor presentation, Feb 23, 2016
Slide 1: February 2016 1
February 2016 1
Slide 2: Forward Looking Statements
February 2016 2 Forward Looking Statements This document includes statements concerning our operating results (including product sales), financial condition and product development milestones, which are “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act
Slide 3: Flamel Technologies Transformed
February 2016 3 Flamel Technologies Transformed • Strong financial condition - profitable with strong cash flow and balance sheet • Two FDA approved products - a third expected in 2016 • New and experienced management team • Robust pipeline Mission: To build a diversified specialty pharmaceutical co
Slide 4: Key Milestones Achieved in 2015
February 2016 4 Key Milestones Achieved in 2015 x Generated over $170M of revenues x Profitable and cash flow positive for first time in company's history x Had successful meeting with FDA on Micropump ® Sodium Oxybate x Presented positive clinical data • LiquiTime ® guaifenesin • Trigger Lock™ hydr
Slide 5: 2016 Expectations
February 2016 5 2016 Expectations • Achieve total product sales of $110 - 130 million, inclusive of FSC Pediatrics • Launch UMD#3 • Integrate and market newly acquired FSC Pediatrics’ products • Start patient registration and dosing for pivotal study of Micropump® sodium oxybate • Begin licensing di
Slide 6: Acquisition of FSC
February 2016 6 Acquisition of FSC
Slide 7: Strategic Rationale
February 2016 7 Strategic Rationale FSC Pediatrics • Commercial stage specialty pharmaceuticals company headquartered Charlotte, NC • Provides commercial infrastructure to leverage for future products • Provides new revenue streams and lessens dependence on Éclat products • Become a more attractive
Slide 8: Terms of the Transaction
February 2016 8 Terms of the Transaction • Fixed acquisition price totals $20.25 million paid over a five year period • $1 million annually for five years • And a final payment in January 2021 of $15.0 million • Variable consideration: • Royalties of 15 % per annum on net sales of the current FSC pr
Slide 9: FSC Sales Force Coverage
February 2016 9 FSC Sales Force Coverage
Slide 10: Marketed Products Portfolio
February 2016 10 Marketed Products Portfolio • Flamel’s Products • Acquired FSC Products
Slide 11: Bloxiverz & Vazculep Overview
February 2016 11 BLOXIVERZ® & VAZCULEP ® Overview * IMS Bloxiverz ® • Indication: Reverses neuromuscular blockades used in surgical procedures • 1 of 3 approved versions of neostigmine methylsulfate injection • Approximately 4 million vials sold annually in the United States* • More details can be f
Slide 12: Karbinol ER & Cefaclor Overview
February 2016 12 Karbinol ER & Cefaclor Overview • Licensed from Tris Pharma in August 2013 • Used for the treatment of seasonal and perennial allergic rhinitis in children 2 years of age and older • Orange book patent protection through March 2029 • Market size for liquids in US estimated at $110 m
Slide 13: AcipHex Sprinkle Overview
February 2016 13 AcipHex Sprinkle Overview • Licensed from Eisai in June 2014 • FDA approved AcipHex Sprinkle in March, 2013 for the treatment of GERD in pediatric patients aged 1 - 11 years • Launched promotional efforts in August 2014 • Market size for liquids in US estimated at $110 million • Pro
Slide 14: Flexichamber Overview
February 2016 14 Flexichamber Overview • Collapsible asthma spacer • Internally developed with a 510 (K) approval • Market size estimated at $50 million • Patents through 2028 • Patient benefits: x Dynamic Portability x Optimal Performance x Simple Assembly x Enhanced Patient Care TRANSFORMING THE T
Slide 15: Flamel's R&D Pipeline
February 2016 15 Flamel’s R&D Pipeline • Micropump® sodium oxybate • LiquiTime® • Trigger Lock™ hydromorphone • Medusa™ e xenatide
Slide 16: Current Pipeline
February 2016 16 Drug/ Technology Indication Proof of Concept Pilot Pivotal Under Review Approved Sales Force UD/UMD 1 # 3 Undisclosed Flamel UD/UMD 1 # 4 Undisclosed Flamel Sodium oxybate/ Micropump® Narcolepsy Flamel Ibuprofen / LiquiTime ® Pain / Fever Perrigo Guaifenesin / LiquiTime ® Respirator
Slide 17: Micropump Sodium Oxybate (FT218)
February 2016 17 FT218 Overview • Extended release oral solid formulation of sodium oxybate using Micropump ® • Studied in 40 healthy volunteers across 2 studies • Profile is consistent with the target of single dose before bedtime • Met with FDA mid 2015 and will submit IND and SPA during 1H 2016 •
Slide 18: LiquiTime OTC
February 2016 18 Overview • Extended release liquid oral suspension for treatment of pain and fever • Ibuprofen & Guaifenesin oral suspension twice - daily dosing confirmed Next Step : • Ibuprofen – IND/CTA filing and pivotal trial initiation in 2 H 2016 • Guaifenesin – Confirmatory PK study in 1 H
Slide 19: Trigger Lock Hydromorphone (FT227)
February 2016 19 FT227 Overview • Abuse - deterrent, extended - release, oral hydromorphone product for treatment of pain – technology is applicable to all opioids • Positive results from two pilot PK studies in healthy volunteers announced in June 2015 • Next step : M eet with the FDA in 1 H 2016 ;
Slide 20: Medusa Exenatide (FT228)
February 2016 20 FT228 Overview • Subcutaneous injection formulation of exenatide , a GLP - 1 (glucagon - like peptide – 1 ) for treatment of Type 2 diabetes • Interim phase I human clinical data reported in December 2015 • PK profile compatible with a release over one week in humans • Next step : C
Slide 21: Flamel's Strengths
February 2016 21 Flamel’s Strengths • Strong intellectual property • Seasoned senior management • Healthy financial situation
Slide 22: Strong Intellectual Property
February 2016 22 Strong Intellectual Property • New patents may be issued targeting each individual product in development where a Flamel drug delivery platform is applied to a specific molecule Platform US Europe Micropump® July 2027 July 2023 LiquiTime® September 2025 April 2023 Trigger Lock™ Apri
Slide 23: Seasoned Senior Management
February 2016 23 Seasoned Senior Management Name Title Appointed Experience Michael S. Anderson Chief Executive Officer 2012 40+ years Pharma Sandy Hatten Senior Vice President, Quality and Regulatory Affairs 2015 30+ years Pharma Phillandas T. Thompson, J.D., M.B.A. Senior Vice President, General C
Slide 24: Condensed Consolidated Statement of Operations
February 2016 24 Condensed Consolidated Statement of Operations (Unaudited) In USD million, except EPS and shares data (million) Nine months ended September 30, 2015 September 30, 2014 Revenue $ 130 $12 COGS (8) (2) R&D (20) (12) SG&A (15) (12) Acquisition Royalty Payments (24) (1) Adj Op. Profit (L
Slide 25: Flamel Technologies Transformed
February 2016 25 Flamel Technologies Transformed • Strong financial condition - Profitable with strong cash flow and balance sheet • Two FDA approved products - a third expected in 2016 • New and experienced management team • Robust pipeline Mission: To build a diversified specialty pharmaceutical c
Slide 26: Appendix
February 2016 26 Appendix
Slide 27: Diversified and Proven Drug Delivery Platforms
February 2016 27 Diversified and Proven Drug Delivery Platforms • Outstanding drug delivery platforms to tackle key challenges in the formulation, in various dosage forms (e . g . capsules, tablets, sachets or oral liquid suspensions ; or injectable for subcutaneous administration) of a broad range
Slide 28: Micropump Platform at a Glance
February 2016 28 Micropump® Platform a t a Glance • Extended/delayed - release of drugs in the GI tract • Precise pharmacokinetics of single or combination of drugs in various formats • Numerous Micropump® - based products successfully tested in human clinical trials Various dosage forms (tablet, ca
Slide 29: Micropump Microparticles for Controlled/Modified Release
February 2016 29 • Microparticles are dispersed in the stomach and pass into the small intestine, after which each microparticle releases the drug at an adjustable rate and over an extended period of time (up to 24 hours) • Drug released at an adjustable rate controlled and/or delayed • Micropump® m
Slide 30: LiquiTime Platform at a Glance
February 2016 30 LiquiTime® Platform at a Glance LiquiTime® is a novel, proprietary and innovative delivery platform allowing the stable L iquid and controlled release formulation of one or several combined drugs over Time LiquiTime® meets challenges faced in the treatment of pediatric and geriatric
Slide 31: LiquiTime for Extended-Release Liquid Suspension
February 2016 31 Each microparticle is individually coated and behaves as an independent micro reservoir Coating • controls diffusion • keeps its integrity • offers good resistance to stress LiquiTime® f or Extended - Release Liquid Suspension L iquid suspension contains small coated drug microparti
Slide 32: Trigger Lock Platform at a Glance
February 2016 32 Trigger Lock™ is a proprietary and innovative delivery platform that enables the controlled release of narcotic and opioid analgesics while deterring their abuse Trigger Lock™ successfully addresses the issues of narcotic/opioid analgesics tampering : x The sustained release Micropu
Slide 33: Trigger Lock SR Microparticles for Abuse Resistance
February 2016 33 1. Drug loaded Micropump® microparticles Sustained Release (SR) microparticles which are resistant to crushing 2. Viscosifying ingredient(s) To prevent abuse by injection after extraction in a small volume of solvent 3. Quenching ingredient(s) To prevent extraction in large volumes
Slide 34: Medusa Platform at a Glance
February 2016 34 Medusa Depot Solubilization and stabilization of drugs Applicable to a wide range of small molecules, peptide and protein drugs Safe, non - immunogenic and fully biodegradable Sustained delivery from 1 to 7 days in human Combination of several different drugs in the same formulation
Slide 35: Medusa Depot for Injection
February 2016 35 Medusa ™ Depot for Injection COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + COO - Na + Vitamin E Polyglutamate chain Drug solution or powder Formulation by simple mixing in water Non - covalent association ( reversible hydrophobic and/or electrostatic interaction)
Slide 36: Reconciliation of Non GAAP to GAAP Results
February 2016 36 Reconciliation of Non GAAP to GAAP Results Flamel Technologies Reconciliation of GAAP to Non GAAP Non GAAP Operating Profit (Loss) 62$ (15)$ Contingent Consideration - Cash Payments 24 2 Contingent Consideration - Fair Value Remeasurement (82) (35) Amortization of R&D Intangibles (9
Slide 37: Headquarters and Contact
February 2016 37 Headquarters 33 avenue du Dr . Georges Levy 69200 Vénissieux (Lyon) France U . S . Commercial Operations 16640 Chesterfield Grove Road, Suite 200 Chesterfield, MO Corporate Contact Phone : + 33 472 783 434 Fax : + 33 472 783 435 E - mail : licensing@flamel . com Specialty Pharmaceut
Flamel Technologies — Investor Presentation (February 2016) on 6ix